Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health
Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health
Related Articles
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe
Britain’s competition watchdog fined U.S. firm Viatris 1.5 million pounds ($1.88 million) on Friday for violating an order during its probe into pharma company Theramex’s…
To Hold or Not to Hold GLP-1s Before Surgery
Dr Anne Peters discusses the conflicting recommendations from FDA and medical societies regarding managing patients on GLP-1s prior to elective surgery.
Weight Stigma
Weight stigma is pervasive across all levels of society, including health care. Understanding the current climate of weight stigma and exploring ways to eradicate it…
High-fat diet stimulated butyric acid metabolism dysbiosis, altered microbiota, and aggravated inflammatory response in collagen-induced arthritis rats – Nutrition & Metabolism
Background Research has demonstrated that obesity may be associated with rheumatoid arthritis (RA). In addition, Dysbiosis of intestinal microbiota and their metabolites has been linked…
Six Months, Thousands of GPTs and Some Big Unknowns: Inside OpenAI’s Deal With BBVA
The bank is evaluating its next steps after seeing early productivity gains from OpenAI’s enterprise tool
Glucagon‐like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta‐analysis of randomised controlled trials
Click on the article title to read more.
Economic Impact of Bariatric Surgery in Australia: 16-Year Results from the 45 and Up Study with Linked Health Data
Obesity Surgery – Bariatric surgery is the most effective long-term therapy for severe obesity; however, empirical investigation of its economic impacts has been based on…
Plasma concentration of gastrointestinal hormones and subjective appetite ratings after diet or bariatric surgery: 1-year results from the DISGAP study
International Journal of Obesity – Plasma concentration of gastrointestinal hormones and subjective appetite ratings after diet or bariatric surgery: 1-year results from the DISGAP study
Tirzepatide in Patients with Obesity and Prediabetes
SURMOUNT-1 was the industry-sponsored trial that led to U.S. FDA approval of tirzepatide — branded as Zepbound — for managing obesity (NEJM JW Gen Med
Global collaborative research in metabolic and bariatric surgery (GCRMBS): current status and directions for the future – BMC Surgery
Obesity has been recognized as a chronic disorder by the World Health Organisation (WHO) and was first reported in the Paleolithic age. In the recent…